Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay

Genes Chromosomes and Cancer

Volumn 47, Issue 12, 2008, Pages 1076-1085

  Bloethner, Sandra ^a   Mould, Arne ^a   Stark, Mitchell ^a   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; EMETINE; MESSENGER RNA;

ARHGEF17 GENE; ARTICLE; CELL LINE; CODON; CONTROLLED STUDY; DENND2D GENE; FGFR3 GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MELANOMA; MICROARRAY ANALYSIS; MISMATCH REPAIR; NONSENSE MUTATION; PRIORITY JOURNAL; RBI GENE; TUMOR SUPPRESSOR GENE;

CODON, NONSENSE; DACTINOMYCIN; DNA-BINDING PROTEINS; EMETINE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MELANOMA; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETINOBLASTOMA PROTEIN; RNA STABILITY; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 57149101313     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20598     Document Type: Article

References (43)

1. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. 1994. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4:35-45.
2. Belgrader P, Cheng J, Maquat LE. 1993. Evidence to implicate translation by ribosomes in the mechanism by which nonsense codons reduce the nuclear level of human triosephosphate isomerase mRNA. Proc Natl Acad Sci USA 90:482-486.
3. Bloethner S, Hemminki K, Thirumaran RK, Chen B, Mueller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. 2006. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Res 16:297-307.
4. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. 2003. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophagecolony stimulating factor) production and breast tumor progression. J Biol Chem 278:29420-29434.
5. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. 2003. ESE-finder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568-3571.
6. Cheng SL, Huang Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ. 2006. Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull 29:655-669.
7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147.
8. de Snoo FA, Hayward NK. 2005. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230:153-186.
9. Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J. Lund melanoma study group; Melanoma genetics consortium. 2003. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73:301-313.
10. Goldberg EK, Glendening JM, Karanjawala Z, Sridhar A, Walker GJ, Hayward NK, Rice AJ, Kurera D, Tebha Y, Fountain JW. 2000. Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet 67:417-431.
11. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. 1997. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660-3663.
12. Hentze MW, Kulozik AE. 1999. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96:307-310.
13. Herbst RA, Mommert S, Casper U, Podewski EK, Kiehl P, Kapp A, Weiss J. 2000. 11q23 allelic loss is associated with regional lymph node metastasis in melanoma. Clin Cancer Res 6:3222-3227.
14. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. 2004. Nonsense-mediated decay approaches the clinic. Nat Genet 36:801-808.
15. Hussein MR. 2004. The TP53 tumor suppressor gene and melanoma tumorigenesis: Is there a relationship? Tumour Biol 25:200-207.
16. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S. 2004. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36:979-983.
17. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. 2004. Manipulation of nonsense mediated decay identifies gene mutations in colon cancer cells with microsatellite instability. Oncogene 23:639-645.
18. Ishigaki Y, Li X, Serin G, Maquat LE. 2001. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 106:607-617.
19. Ivanov I, Lo KC, Hawthorn L, Cowell JK, Ionov Y. 2007. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene 26:2873-2884.
20. Jang JH, Shin KH, Park JG. 2001. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61:3541-3543.
21. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, III, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
22. Li S, Wilkinson MF. 1998. Nonsense surveillance in lymphocytes? Immunity 8:135-141.
23. Maquat LE. 2005. Nonsense-mediated mRNA decay in mammals. J Cell Sci 118:1773-1776.
24. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, Sarkaria IS, Pham D, Singh B, Miner TL, Fewell GA, Fulton LL, Mardis ER, Wilson RK, Kris MG, Rusch VW, Varmus H, Pao W. 2007. Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2:e426.
25. McGuinness C, Wesley UV. 2008. Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation. Front Biosci 13:2435-2443.
26. Mercola D, Welsh J. 2004. From mRNA to tumor suppressor. Nat Genet 36:937-938.
27. Nagy E, Maquat LE. 1998. A rule for termination-codon position within intron-containing genes: When nonsense affects RNA abundance. Trends Biochem Sci 23:198-199.
28. Noensie EN, Dietz HC. 2001. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol 19:434-439.
29. Papp T, Niemetz A, Dosdahl N, Kumar K, Schiffmann D. 2007. Mutational analysis of Chk1, Chk2, Apaf1, and Rb1 in human malignant melanoma cell lines. Oncol Rep 17:135-140.
30. Pollock PM, Welch J, Hayward NK. 2001. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 61:1154-1161.
31. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158-7162.
32. Qi H, Fournier A, Grenier J, Fillion C, Labrie Y, Labrie C. 2003. Isolation of the novel human guanine nucleotide exchange factor Src homology 3 domain-containing guanine nucleotide exchange factor (SGEF) and of C-terminal SGEF, an N-terminally truncated form of SGEF, the expression of which is regulated by androgen in prostate cancer cells. Endocrinology 144:1742-1752.
33. Robertson GP, Goldberg EK, Lugo TG, Fountain JW. 1999. Functional localization of a melanoma tumor suppressor gene to a small (< or 5 2 Mb) region on 11q23. Oncogene 18:3173-3180.
34. Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y. 2005. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet 161:97-103.
35. Sibley K, Stern P, Knowles MA. 2001. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20:4416-4418.
36. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J. 2000. Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer 28:121-125.
37. Sobell HM. 1985. Actinomycin and DNA transcription. Proc Natl Acad Sci USA 82:5328-5331.
38. Stark M, Hayward N. 2007. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67:2632-2642.
39. Sun X, Maquat LE. 2000. mRNA surveillance in mammalian cells: the relationship between introns and translation termination. Rna 6:1-8.
40. Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. 2007. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int J Cancer 121:1976-1983.
41. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC, Radvanyi F. 2002. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10:819-824.
42. Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF, Trent JM, Mann GJ, Hayward NK. 2004. Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer 41:56-64.
43. Weischenfeldt J, Lykke-Andersen J, Porse B. 2005. Messenger RNA surveillance: Neutralizing natural nonsense. Curr Biol 15:R559-562.